The DIDB Concomitant Meds Navigator was updated in April and is now available in the Tools.
This update includes 42 drug interaction characteristics involving 22 compounds. These encompass substrates of CYP2C9, CYP3A, UGT1A9, and OATP1B1 (N = 12); inhibitors of CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A, UGT1A1, P-gp, BCRP, OCT2, MATE1, and MATE2-k (N = 23); and inducers of CYP2C19, CYP3A, UGT1A1, and P-gp (N = 7).
Four drugs were identified as sensitive substrates, all for CYP3A, based on DDI studies with the strong CYP3A inhibitors itraconazole (N = 3) and ketoconazole (N = 1). One drug was identified as a strong CYP2D6 inhibitor and one as a strong CYP3A inducer based on dedicated DDI studies using the index substrates dextromethorphan and midazolam, respectively.
You may access the Navigator to view the full list of compounds, along with supporting study details and additional pharmacokinetic information.
As always, feel free to contact us if you have any questions or comments.